论文部分内容阅读
目的:探索DNA酶Ⅰ处理后骨髓间充质干细胞降低急性肺栓塞的发生。方法:体外培养小鼠骨髓间充质干细胞。C57小鼠分PBS注射组、10U/mL DNaseⅠ-PBS注射组、正常BMSCs注射组、DNaseⅠ处理后BMSCs注射组。PBS注射组与正常BMSCs注射组尾静脉注射PBS或临界致死剂量的BMSCs,脏器组织学检测,PBS注射组对照,观察急性死亡率;比较正常BMSCs与DNaseⅠ处理后BMSCs体外增殖、分化能力和悬液中细胞聚集状态;DNaseⅠ处理后BMSCs注射组注射DNaseⅠ处理后3×106个BMSCs 5ml/kg观察急性死亡率。结果:PBS注射组相比正常BMSCs注射组急性死亡率为60%、心肺异常、肺血管内异染物质,急性肺栓塞;DNaseⅠ预处理不影响BMSCs体外增殖分化能力;DNaseⅠ处理BMSCs较正常BMSCs聚集成团细胞比例显著下降。DNaseⅠ处理后BMSCs注射组的急性死亡率为23.3%,与正常BMSCs注射组比较差异显著。结论:DNaseⅠ预处理不影响BM-SCs的生物学特性并能抑制单细胞聚集降低静脉注射BMSCs所导致的急性肺栓塞。
Objective: To explore the effect of DNase Ⅰ treatment on the bone marrow mesenchymal stem cells to reduce acute pulmonary embolism. Methods: Mouse bone marrow mesenchymal stem cells were cultured in vitro. C57 mice were divided into PBS injection group, 10 U / mL DNase I-PBS injection group, normal BMSCs injection group and DNase I-treated BMSCs injection group. BMSCs were injected into tail vein of PBS injection group or normal BMSCs injection group or critical lethal dose of BMSCs, histological examination of organ and PBS injection group were compared to observe the acute death rate. Compared with normal BMSCs and DNaseⅠ treated BMSCs proliferation, differentiation ability and suspension The aggregation of cells in the liquid state; After DNase Ⅰ treatment BMSCs injection group injected with DNase Ⅰ 3 × 106 BMSCs 5ml / kg to observe the acute death rate. Results: Compared with normal BMSCs group, the acute death rate of PBS injection group was 60%, cardio-pulmonary dysfunction, pulmonary vascular disease and acute pulmonary embolism. DNaseⅠ pretreatment did not affect the proliferation and differentiation of BMSCs in vitro. DNaseⅠ-treated BMSCs accumulated more than normal BMSCs The proportion of cells into the group decreased significantly. The acute death rate of BMSCs injection group after DNaseⅠ treatment was 23.3%, which was significantly different from that of normal BMSCs injection group. Conclusion: DNase Ⅰ pretreatment does not affect the biological characteristics of BM-SCs and can inhibit the aggregation of single cells to reduce the acute pulmonary embolism caused by intravenous injection of BMSCs.